Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
Koiji SasakiFady Gh HaddadNicholas James ShortNitin JainGhayas IssaElias J JabbourHagop M KantarjianPublished in: Cancer (2023)
Although the outcome of Ph-positive CML has improved significantly since 2000, the SEER data still shows differences in outcomes among patient subsets, some anticipated (worse OS in older patients accounted by the relative OS), but others that suggest less than universal access and affordability of this therapy (among poorer patients) in the United States.
Keyphrases
- chronic myeloid leukemia
- end stage renal disease
- ejection fraction
- chronic kidney disease
- public health
- acute lymphoblastic leukemia
- peritoneal dialysis
- prognostic factors
- electronic health record
- stem cells
- big data
- mesenchymal stem cells
- bone marrow
- cell therapy
- adverse drug
- artificial intelligence
- smoking cessation